Cytokinetics Action
ActionActionPrix
Questions fréquentes
Quelle est la capitalisation boursière de Cytokinetics ?
Quel est le bénéfice par action (BPA) de Cytokinetics ?
Quelles sont les évaluations des analystes et le prix cible de l'action Cytokinetics ?
Quel est le chiffre d'affaires de Cytokinetics sur les douze derniers mois ?
Quel est l'EBITDA de Cytokinetics ?
Quel est le flux de trésorerie disponible de Cytokinetics ?
Quel est le bêta à 5 ans de l'action Cytokinetics ?
Combien d'employés compte Cytokinetics, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Cytokinetics ?
Finances
Capitalisation boursière
6,92 Md $USbêta sur 5 ans
0,83BPA (TTM)
-5,388 $USFree Float
116,44 MRecettes (TTM)
3,22 M $USEBITDA (TTM)
-511,14 M $USCash-flow disponible (TTM)
-407,05 M $USCotation
Notes des analystes
L'objectif de prix est de 83,75 $US et l'action est analysée par 17 analystes.
Acheter
14
Hold
3
Vendre
0
Informations
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
423
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire